Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression

Journal of Immunology

Volumn 185, Issue 10, 2010, Pages 6003-6012

  Feng, Di ^a,b   Sangster Guity, Niquiche ^b   Stone, Rivka ^a,b   Korczeniewska, Justyna ^a,b   Mancl, Margo E ^b   Fitzgerald Bocarsly, Patricia ^c   Barnes, Betsy J ^a,b  

^a Department of Biochemistry and Molecular Biology ^*  (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE 1; INTERFERON REGULATORY FACTOR 5; TRANSCRIPTION FACTOR SIN3A; TRICHOSTATIN A;

ACETYLATION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE MAPPING; HUMAN; HUMAN CELL; IFNA GENE; IL6 GENE; ISRE GENE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TNFALPHA GENE; TRANSCRIPTION INITIATION;

CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CYTOKINES; GENE EXPRESSION; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INTERFERON REGULATORY FACTORS; POLYMERASE CHAIN REACTION; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 78650637976     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000482     Document Type: Article

References (74)

1. Grunstein, M. 1997. Histone acetylation in chromatin structure and transcription. Nature 389:349-352.
2. Cress, W. D., and E. Seto. 2000. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184:1-16.
3. Nusinzon, I., and C. M. Horvath. 2005. Histone deaceylases as transcriptional activators? Role reversal in inducible gene regulation. Sci. STKE 2005: re11.
4. Mariadason, J. M., G. A. Corner, and L. H. Augenlicht. 2000. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60:4561-4572.
5. Chambers, A. E., S. Banerjee, T. Chaplin, J. Dunne, S. Debernardi, S. P. Joel, and B. D. Young. 2003. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur. J. Cancer 39:1165-1175.
6. Bannister, A. J., T. Oehler, D. Wilhelm, P. Angel, and T. Kouzarides. 1995. Stimulation of c-Jun. activity by CBP: c-Jun. residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Oncogene 11:2509-2514.
7. Yuan, W., G. Condorelli, M. Caruso, A. Felsani, and A. Giordano. 1996. Human p300 protein is a coactivator for the transcription factor MyoD. J. Biol. Chem. 271:9009-9013.
8. Kamei, Y., L. Xu, T. Heinzel, J. Torchia, R. Kurokawa, B. Gloss, S. C. Lin, R. A. Heyman, D. W. Rose, C. K. Glass, and M. G. Rosenfeld. 1996. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403-414.
9. Zhang, J. J., U. Vinkemeier, W. Gu, D. Chakravarti, C. M. Horvath, and J. E. Darnell, Jr. 1996. Two contact regions between Stat1 and CBP/p300 in interferon γ signaling. Proc. Natl. Acad. Sci. USA 93:15092-15096.
10. Klampfer, L., J. Huang, L. A. Swaby, and L. Augenlicht. 2004. Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 279:30358-30368.
11. Agalioti, T., G. Chen, and D. Thanos. 2002. Deciphering the transcriptional histone acetylation code for a human gene. Cell 111:381-392.
12. Nusinzon, I., and C. M. Horvath. 2003. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl. Acad. Sci. USA 100:14742-14747.
13. Sakamoto, S., R. Potla, and A. C. Larner. 2004. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferonstimulated early response genes. J. Biol. Chem. 279:40362-40367.
14. Chang, H. M., M. Paulson, M. Holko, C. M. Rice, B. R. Williams, I. Marié, and D. E. Levy. 2004. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl. Acad. Sci. USA 101:9578-9583.
15. Leoni, F., G. Fossati, E. C. Lewis, J. K. Lee, G. Porro, P. Pagani, D. Modena, M. L. Moras, P. Pozzi, L. L. Reznikov, et al. 2005. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1-15.
16. Bode, K. A., K. Schroder, D. A. Hume, T. Ravasi, K. Heeg, M. J. Sweet, and A. H. Dalpke. 2007. Histone deacetylase inhibitors decrease Toll-like receptormediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 122:596-606.
17. Joseph, J., G. Mudduluru, S. Antony, S. Vashistha, P. Ajitkumar, and K. Somasundaram. 2004. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23:6304-6315.
18. Mesplède, T., S. Navarro, P. Génin, P. Morin, M. L. Island, E. Bonnefoy, and A. Civas. 2003. Positive and negative control of virus-induced interferon-A gene expression. Autoimmunity 36:447-455.
19. Barnes, B. J., P. A. Moore, and P. M. Pitha. 2001. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J. Biol. Chem. 276:23382-23390.
20. Barnes, B. J., M. J. Kellum, A. E. Field, and P. M. Pitha. 2002. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol. Cell. Biol. 22:5721-5740.
21. Barnes, B. J., J. Richards, M. Mancl, S. Hanash, L. Beretta, and P. M. Pitha. 2004. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J. Biol. Chem. 279:45194-45207.
22. Schoenemeyer, A., B. J. Barnes, M. E. Mancl, E. Latz, N. Goutagny, P. M. Pitha, K. A. Fitzgerald, and D. T. Golenbock. 2005. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J. Biol. Chem. 280:17005-17012.
23. Takaoka, A., H. Yanai, S. Kondo, G. Duncan, H. Negishi, T. Mizutani, S. Kano, K. Honda, Y. Ohba, T. W. Mak, and T. Taniguchi. 2005. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434:243-249.
24. Yanai, H., H. M. Chen, T. Inuzuka, S. Kondo, T. W. Mak, A. Takaoka, K. Honda, and T. Taniguchi. 2007. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc. Natl. Acad. Sci. USA 104:3402-3407.
25. Mancl, M. E., G. Hu, N. Sangster-Guity, S. L. Olshalsky, K. Hoops, P. Fitzgerald-Bocarsly, P. M. Pitha, K. Pinder, and B. J. Barnes. 2005. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J. Biol. Chem. 280:21078-21090.
26. Dent, C. L., S. J. Macbride, N. A. Sharp, and D. R. Gewert. 1996. Relative transcriptional inducibility of the human interferon-alpha subtypes conferred by the virus-responsive enhancer sequence. J. Interferon Cytokine Res. 16:99-107.
27. Yeow, W. S., W. C. Au, Y. T. Juang, C. D. Fields, C. L. Dent, D. R. Gewert, and P. M. Pitha. 2000. Reconstitution of virus-mediated expression of interferon alpha genes in human fibroblast cells by ectopic interferon regulatory factor-7. J. Biol. Chem. 275:6313-6320.
28. Cheung, S. C., S. K. Chattopadhyay, J. W. Hartley, H. C. Morse, III, and P. M. Pitha. 1991. Aberrant expression of cytokine genes in peritoneal macrophages from mice infected with LP-BM5 MuLV, a murine model of AIDS. J. Immunol. 146:121-127.
29. Hu, G., and B. J. Barnes. 2009. IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J. Biol. Chem. 284:2767-2777.
30. Barnes, B. J., A. E. Field, and P. M. Pitha-Rowe. 2003. Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J. Biol. Chem. 278:16630-16641.
31. Jepsen, K., and M. G. Rosenfeld. 2002. Biological roles and mechanistic actions of co-repressor complexes. J. Cell Sci. 115:689-698.
32. Li, J., Q. Lin, W. Wang, P. Wade, and J. Wong. 2002. Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes Dev. 16:687-692.
33. Weaver, B. K., K. P. Kumar, and N. C. Reich. 1998. Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1. Mol. Cell. Biol. 18:1359-1368.
34. Yoneyama, M., W. Suhara, Y. Fukuhara, M. Fukuda, E. Nishida, and T. Fujita. 1998. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17:1087-1095.
35. Savitsky, D., T. Tamura, H. Yanai, and T. Taniguchi. 2010. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol. Immunother. 59:489-510.
36. Clément, J. F., A. Bibeau-Poirier, S. P. Gravel, N. Grandvaux, E. Bonneil, P. Thibault, S. Meloche, and M. J. Servant. 2008. Phosphorylation of IRF-3 on Ser 339 generates a hyperactive form of IRF-3 through regulation of dimerization and CBP association. J. Virol. 82:3984-3996.
37. Tang, X., J. S. Gao, Y. J. Guan, K. E. McLane, Z. L. Yuan, B. Ramratnam, and Y. E. Chin. 2007. Acetylation-dependent signal transduction for type I interferon receptor. Cell 131:93-105.
38. Cheng, T. F., S. Brzostek, O. Ando, S. Van Scoy, K. P. Kumar, and N. C. Reich. 2006. Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection. J. Immunol. 176:7462-7470.
39. Caillaud, A., A. Prakash, E. Smith, A. Masumi, A. G. Hovanessian, D. E. Levy, and I. Marié. 2002. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J. Biol. Chem. 277:49417-49421.
40. Chen, W., and W. E. Royer. 2010. Structural insights into interferon regulatory factor activation. Cell. Signal. 22:883-887.
41. Qin, B. Y., C. Liu, H. Srinath, S. S. Lam, J. J. Correia, R. Derynck, K. Lin, and K. Lin. 2005. Crystal structure of IRF-3 in complex with CBP. Structure 13:1269-1277.
42. Masumi, A., Y. Yamakawa, H. Fukazawa, K. Ozato, and K. Komuro. 2003. Interferon regulatory factor-2 regulates cell growth through its acetylation. J. Biol. Chem. 278:25401-25407.
43. Wathelet, M. G., C. H. Lin, B. S. Parekh, L. V. Ronco, P. M. Howley, and T. Maniatis. 1998. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol. Cell 1:507-518.
44. Au, W. C., and P. M. Pitha. 2001. Recruitment of multiple interferon regulatory factors and histone acetyltransferase to the transcriptionally active interferon a promoters. J. Biol. Chem. 276:41629-41637.
45. Génin, P., R. Lin, J. Hiscott, and A. Civas. 2009. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 29:3435-3450.
46. Baek, S. H., K. A. Ohgi, D. W. Rose, E. H. Koo, C. K. Glass, and M. G. Rosenfeld. 2002. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 110:55-67.
47. Hong, S. H., and M. L. Privalsky. 2000. The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol. Cell. Biol. 20:6612-6625.
48. Hoberg, J. E., F. Yeung, and M. W. Mayo. 2004. SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol. Cell 16:245-255.
49. Kozyrev, S. V., and M. E. Alarcon-Riquelme. 2007. The genetics and biology of Irf5-mediated signaling in lupus. Autoimmunity 40:591-601.
50. Moser, K. L., J. A. Kelly, C. J. Lessard, and J. B. Harley. 2009. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 10:373-379.
51. Feng, D., R. C. Stone, M. L. Eloranta, N. Sangster-Guity, G. Nordmark, S. Sigurdsson, C. Wang, G. Alm, A. C. Syvänen, L. Rönnblom, and B. J. Barnes. 2010. Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum. 62:562-573.
52. Niewold, T. B., J. A. Kelly, M. H. Flesch, L. R. Espinoza, J. B. Harley, and M. K. Crow. 2008. Association of the IRF5 risk haplotype with high serum interferon-a activity in systemic lupus erythematosus patients. Arthritis Rheum. 58:2481-2487.
53. Kariuki, S. N., K. A. Kirou, E. J. MacDermott, L. Barillas-Arias, M. K. Crow, and T. B. Niewold. 2009. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J. Immunol. 182:34-38.
54. Rönnblom, L., M. L. Eloranta, and G. V. Alm. 2006. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 54:408-420.
55. Lee, P. Y., Y. Kumagai, Y. Li, O. Takeuchi, H. Yoshida, J. Weinstein, E. S. Kellner, D. Nacionales, T. Barker, K. Kelly-Scumpia, et al. 2008. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J. Exp. Med. 205:2995-3006.
56. Kim, W. U., A. Sreih, and R. Bucala. 2009. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun. Rev. 8:204-208.
57. Lenert, P. 2010. Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA-and/or RNA-like analogues for treating lupus. Clin. Exp. Immunol. 161:208-222.
58. Leoni, F., A. Zaliani, G. Bertolini, G. Porro, P. Pagani, P. Pozzi, G. Donà, G. Fossati, S. Sozzani, T. Azam, et al. 2002. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. USA 99:2995-3000.
59. Mishra, N., C. M. Reilly, D. R. Brown, P. Ruiz, and G. S. Gilkeson. 2003. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111:539-552.
60. Reddy, P., T. Teshima, M. Kukuruga, R. Ordemann, C. Liu, K. Lowler, and J. L. Ferrara. 2001. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 194:1433-1440.
61. Chung, Y. L., M. Y. Lee, A. J. Wang, and L. F. Yao. 2003. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8:707-717.
62. Nishida, K., T. Komiyama, S. Miyazawa, Z. N. Shen, T. Furumatsu, H. Doi, A. Yoshida, J. Yamana, M. Yamamura, Y. Ninomiya, et al. 2004. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21 (WAF1/Cip1) expression. Arthritis Rheum. 50:3365-3376.
63. Reilly, C. M., N. Mishra, J. M. Miller, D. Joshi, P. Ruiz, V. M. Richon, P. A. Marks, and G. S. Gilkeson. 2004. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J. Immunol. 173:4171-4178.
64. Present, D. H., P. Rutgeerts, S. Targan, S. B. Hanauer, L. Mayer, R. A. van Hogezand, D. K. Podolsky, B. E. Sands, T. Braakman, K. L. DeWoody, et al. 1999. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340:1398-1405.
65. Leonardi, C. L., J. L. Powers, R. T. Matheson, B. S. Goffe, R. Zitnik, A. Wang, A. B. Gottlieb; Etanercept Psoriasis Study Group. 2003. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349:2014-2022.
66. Lee, J. Y., N. A. Kim, A. Sanford, and K. E. Sullivan. 2003. Histone acetylation and chromatin conformation are regulated separately at the TNF-a promoter in monocytes and macrophages. J. Leukoc. Biol. 73:862-871.
67. Chen, W., S. S. Lam, H. Srinath, Z. Jiang, J. J. Correia, C. A. Schiffer, K. A. Fitzgerald, K. Lin, and W. E. Royer, Jr. 2008. Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. Nat. Struct. Mol. Biol. 15:1213-1220.
68. Balkhi, M. Y., K. A. Fitzgerald, and P. M. Pitha. 2008. Functional regulation of MyD88 activated interferon regulatory factor 5 by K63-linked polyubiquitination. Mol. Cell. Biol. 28:7296-7308.
69. Vogelauer, M., J. Wu, N. Suka, and M. Grunstein. 2000. Global histone acetylation and deacetylation in yeast. Nature 408:495-498.
70. Yamagoe, S., T. Kanno, Y. Kanno, S. Sasaki, R. M. Siegel, M. J. Lenardo, G. Humphrey, Y. Wang, Y. Nakatani, B. H. Howard, and K. Ozato. 2003. Interaction of histone acetylases and deacetylases in vivo. Mol. Cell. Biol. 23:1025-1033.
71. Cai, R., P. Kwon, Y. Yan-Neale, L. Sambuccetti, D. Fischer, and D. Cohen. 2001. Mammalian histone deacetylase 1 protein is posttranslationally modified by phosphorylation. Biochem. Biophys. Res. Commun. 283:445-453.
72. Pflum, M. K., J. K. Tong, W. S. Lane, and S. L. Schreiber. 2001. Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation. J. Biol. Chem. 276:47733-47741.
73. David, G., M. A. Neptune, and R. A. DePinho. 2002. SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J. Biol. Chem. 277:23658-23663.
74. Boggio, R., and S. Chiocca. 2005. Gam1 and the SUMO pathway. Cell Cycle 4:533-535.